Cystic Fibrosis
3
Companies
35
Drug Programs
15
Phase 3
0
Upcoming PDUFAs
Vertex Pharmaceuticals Incorporated
Tezacaftor/Ivacaftor
Vertex Pharmaceuticals Incorporated
ELX/TEZ/IVA
Vertex Pharmaceuticals Incorporated
LUM/IVA
Vertex Pharmaceuticals Incorporated
VX-661 plus ivacaftor combination
Vertex Pharmaceuticals Incorporated
Ivacaftor
Vertex Pharmaceuticals Incorporated
IVA
Vertex Pharmaceuticals Incorporated
Lumacaftor
Vertex Pharmaceuticals Incorporated
VX-445/TEZ/IVA
Vertex Pharmaceuticals Incorporated
TEZ
Vertex Pharmaceuticals Incorporated
TEZ/IVA
Vertex Pharmaceuticals Incorporated
VX-121/TEZ/D-IVA
Vertex Pharmaceuticals Incorporated
VX-661/Ivacaftor
Vertex Pharmaceuticals Incorporated
VX-770
Insmed Incorporated
Liposomal amikacin for inhalation
Vertex Pharmaceuticals Incorporated
VX-659/TEZ/IVA
Vertex Pharmaceuticals Incorporated
VX-659
Insmed Incorporated
Placebo
Vertex Pharmaceuticals Incorporated
Placebo matched to VX-661
Vertex Pharmaceuticals Incorporated
VX-445
Vertex Pharmaceuticals Incorporated
VX-152
Galapagos NV
GLPG2737
Galapagos NV
GLPG1837 dose 1
Galapagos NV
GLPG2222 50 mg
Galapagos NV
GLPG2222 150 mg q.d.
Galapagos NV
GLPG1837 dose 2
Insmed Incorporated
Arikayce™
Vertex Pharmaceuticals Incorporated
Ivacaftor 25 mg/75 mg
Vertex Pharmaceuticals Incorporated
VX-121
Insmed Incorporated
Arikayce™ 560 mg
Vertex Pharmaceuticals Incorporated
VX-661
Insmed Incorporated
ARIKACE™
Vertex Pharmaceuticals Incorporated
VX-440
Vertex Pharmaceuticals Incorporated
Placebo (matched to VX-121 suspension)
Vertex Pharmaceuticals Incorporated
VX-809
Vertex Pharmaceuticals Incorporated
Tezacaftor/Ivacaftor matching placebo
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | Tezacaftor/Ivacaftor | Phase 3 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | ELX/TEZ/IVA | Phase 3 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | LUM/IVA | Phase 3 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | VX-661 plus ivacaftor combination | Phase 3 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | Ivacaftor | Phase 3 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | IVA | Phase 3 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | Lumacaftor | Phase 3 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | VX-445/TEZ/IVA | Phase 3 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | TEZ | Phase 3 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | TEZ/IVA | Phase 3 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | VX-121/TEZ/D-IVA | Phase 3 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | VX-661/Ivacaftor | Phase 3 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | VX-770 | Phase 3 | — | — | — |
| INSM Insmed Incorporated | Liposomal amikacin for inhalation | Phase 3 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | VX-659/TEZ/IVA | Phase 3 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | VX-659 | Phase 2 | — | — | — |
| INSM Insmed Incorporated | Placebo | Phase 2 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | Placebo matched to VX-661 | Phase 2 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | VX-445 | Phase 2 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | VX-152 | Phase 2 | — | — | — |
| GLPG Galapagos NV | GLPG2737 | Phase 2 | — | — | — |
| GLPG Galapagos NV | GLPG1837 dose 1 | Phase 2 | — | — | — |
| GLPG Galapagos NV | GLPG2222 50 mg | Phase 2 | — | — | — |
| GLPG Galapagos NV | GLPG2222 150 mg q.d. | Phase 2 | — | — | — |
| GLPG Galapagos NV | GLPG1837 dose 2 | Phase 2 | — | — | — |
| INSM Insmed Incorporated | Arikayce™ | Phase 2 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | Ivacaftor 25 mg/75 mg | Phase 2 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | VX-121 | Phase 2 | — | — | — |
| INSM Insmed Incorporated | Arikayce™ 560 mg | Phase 2 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | VX-661 | Phase 2 | — | — | — |
| INSM Insmed Incorporated | ARIKACE™ | Phase 2 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | VX-440 | Phase 2 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | Placebo (matched to VX-121 suspension) | Phase 2 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | VX-809 | Phase 2 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | Tezacaftor/Ivacaftor matching placebo | Phase 2 | — | — | — |
Not Financial Advice
All predictions are probabilistic and based on historical data. Past performance does not guarantee future results. Consult a qualified financial advisor.